Publication Name	World Journal of Clinical Cases
Manuscript ID	45251
Country	Japan

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Ken Sato, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Masayasu Andou, Yoshihiro Matsuda, Toshio Uraoka, Hiroshi Ohnishi and Hiroaki Okamoto
Funding Agency and Grant Number
Corresponding Author	Ken Sato, MD, PhD, Assistant Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp
Key Words	Direct-acting antiviral agent failure; Hepatitis C; Genotype 2; Ribavirin; Sofosbuvir; Case report
Core Tip	The effectiveness of sofosbuvir/ribavirin (SOF/RBV) therapy was unknown for patients who experienced failure of ombitasvir/paritaprevir/ritonavir plus ribavirin therapy and had hepatitis C virus genotype 2. Although there were only 2 patients, SOF/RBV therapy was effective. However, both patients experienced adverse events including unanticipated development or deterioration of autoimmune diseases. Because SOF/RBV therapy is generally well-tolerated, one of the patients was considered a specific case. However, the cases suggest SOF/RBV therapy should be carefully applied in case of the existence of baseline autoimmune disease. Our case reports warrant future studies, but careful observation during and after treatment is required.
Citation	Sato K, Yamazaki Y, Kobayashi T, Satoshi Takakusagi S, Horiguchi N, Kakizaki S, Andou M, Matsuda Y, Uraoka T, Ohnishi H, Okamoto H. Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. World J Clin Cases 2019; 7(9): 1043-1052

Received	2018-12-26 01:16
Peer-Review Started	2018-12-27 07:54
To Make the First Decision	2019-01-21 02:24
Return for Revision	2019-01-27 03:41
Revised	2019-02-23 09:07
Second Decision	2019-03-15 08:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-03-16 22:48
Articles in Press	2019-03-16 22:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-05-06 06:21

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com